Increase in prevalence of anti-HTLV-III in haemophiliacs

Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia.

Leukemia·2014

[How effective is rituximab in rheumatoid arthritis?: lessons learned from clinical practice].

Zeitschrift fur Rheumatologie·2009

[Association between histopathologic type II synovitis and increased amounts of pyridinoline in synovial tissue samples in rheumatoid arthritis].

Zeitschrift fur Rheumatologie·2008

Colour duplex sonography of finger arteries in vasculitis and in systemic sclerosis.

Annals of the rheumatic diseases·2006

Characterisation of the cell type-specificity of collagenase 3 mRNA expression in comparison with membrane type 1 matrix metalloproteinase and gelatinase A in the synovial membrane in rheumatoid arthritis.

Annals of the rheumatic diseases·2002

Characterization of collagenase 3 (matrix metalloproteinase 13) messenger RNA expression in the synovial membrane and synovial fibroblasts of patients with rheumatoid arthritis.

Arthritis and rheumatism·1999

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

Lancet (London, England)·2026

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Lancet (London, England)·2026

A trembling detour to the diagnosis of encephalitis: a neuroborreliosis case report.

Lancet (London, England)·2026

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial.

Lancet (London, England)·2026

Prolonged low-dose intravenous thrombolysis in early recurrent stroke.

Neurologia i neurochirurgia polska·2026

HLA-DRB1 Polymorphisms Modulate the Dynamic Compatibility between the Presentation of EBNA1400-413 and MBP85-99.

ACS omega·2026

Quantification of blood-based neurovascular unit biomarkers: an analytical platform comparison study.

Resuscitation plus·2026

HBsAg seroclearance with HBV DNA <100 IU/mL and long-term risks of adverse liver events, all-cause mortality, and cause-specific mortality in chronic hepatitis B: a prospective cohort study.

The Lancet regional health. Western Pacific·2026

Cost-effectiveness and budget impact of Luspatercept in Thai adults with transfusion-dependent beta-thalassaemia: a multi-state Markov model based on national claims data.

Journal of pharmaceutical policy and practice·2026

Unraveling the Cause of Hemolytic Anemia in the Emergency Department: A Destructive Path.

Cureus·2026

Related Experiment Videos

Increase in prevalence of anti-HTLV-III in haemophiliacs

Related Concept Videos

Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia.

[How effective is rituximab in rheumatoid arthritis?: lessons learned from clinical practice].

[Association between histopathologic type II synovitis and increased amounts of pyridinoline in synovial tissue samples in rheumatoid arthritis].

Colour duplex sonography of finger arteries in vasculitis and in systemic sclerosis.

Characterisation of the cell type-specificity of collagenase 3 mRNA expression in comparison with membrane type 1 matrix metalloproteinase and gelatinase A in the synovial membrane in rheumatoid arthritis.

Characterization of collagenase 3 (matrix metalloproteinase 13) messenger RNA expression in the synovial membrane and synovial fibroblasts of patients with rheumatoid arthritis.

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

A trembling detour to the diagnosis of encephalitis: a neuroborreliosis case report.

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial.

Prolonged low-dose intravenous thrombolysis in early recurrent stroke.

HLA-DRB1 Polymorphisms Modulate the Dynamic Compatibility between the Presentation of EBNA1400-413 and MBP85-99.

Quantification of blood-based neurovascular unit biomarkers: an analytical platform comparison study.

HBsAg seroclearance with HBV DNA <100 IU/mL and long-term risks of adverse liver events, all-cause mortality, and cause-specific mortality in chronic hepatitis B: a prospective cohort study.

Cost-effectiveness and budget impact of Luspatercept in Thai adults with transfusion-dependent beta-thalassaemia: a multi-state Markov model based on national claims data.

Unraveling the Cause of Hemolytic Anemia in the Emergency Department: A Destructive Path.

Related Experiment Videos

Increase in prevalence of anti-HTLV-III in haemophiliacs

Related Concept Videos

Related Articles